Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Globe Newswire26-02-2024, 14:05
New Global Study: Dangerous Nighttime Heat Rising in 83% of Global Cities Analyzed, Becoming More Oppressive, And More Frequent 20-11-2025, 02:03